Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.

Hansen TF, Christensen Rd, Andersen RF, Sørensen FB, Johnsson A, Jakobsen A.

Br J Cancer. 2013 Sep 3;109(5):1243-51. doi: 10.1038/bjc.2013.448. Epub 2013 Aug 6.

2.

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ.

Clin Cancer Res. 2011 Sep 1;17(17):5783-92. doi: 10.1158/1078-0432.CCR-11-1115. Epub 2011 Jul 26.

3.

Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.

Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isıkdogan A, Ozkan M, Coskun U, Buyukberber S.

Asian Pac J Cancer Prev. 2012;13(3):1059-63.

4.

Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer.

Hansen TF, Nielsen BS, Sørensen FB, Johnsson A, Jakobsen A.

Mol Cancer Ther. 2014 Sep;13(9):2238-45. doi: 10.1158/1535-7163.MCT-14-0131. Epub 2014 Aug 19.

5.

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Johnsson A, Hagman H, Frödin JE, Berglund A, Keldsen N, Fernebro E, Sundberg J, De Pont Christensen R, Garm Spindler KL, Bergström D, Jakobsen A.

Ann Oncol. 2013 Sep;24(9):2335-41. doi: 10.1093/annonc/mdt236. Epub 2013 Jun 19.

6.

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV.

Ann Oncol. 2013 Oct;24(10):2554-9. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17.

7.

Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.

Lee JJ, Chu E.

Clin Colorectal Cancer. 2014 Sep;13(3):135-44. doi: 10.1016/j.clcc.2014.02.001. Epub 2014 Feb 27. Review.

8.

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.

Hansen TF, Sørensen FB, Lindebjerg J, Jakobsen A.

BMC Cancer. 2012 Mar 8;12:83. doi: 10.1186/1471-2407-12-83.

9.

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E.

J Clin Oncol. 2012 Oct 10;30(29):3588-95. doi: 10.1200/JCO.2012.42.5355. Epub 2012 Sep 10.

10.

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.

Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ.

PLoS One. 2013 Jul 4;8(7):e66774. doi: 10.1371/journal.pone.0066774. Print 2013.

11.

Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.

Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, Schmiegel W, Reinacher-Schick A.

Z Gastroenterol. 2011 Oct;49(10):1398-406. doi: 10.1055/s-0031-1281752. Epub 2011 Sep 30. Review.

PMID:
21964893
12.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.

13.

Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.

Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1900-10. eCollection 2015.

14.

The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.

García-Alfonso P, Grande E, Polo E, Afonso R, Reina JJ, Jorge M, Campos JM, Martínez V, Angeles C, Montagut C.

Angiogenesis. 2014 Oct;17(4):805-21. doi: 10.1007/s10456-014-9433-6. Epub 2014 May 3. Review.

PMID:
24793846
15.

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.

Spencer SK, Pommier AJ, Morgan SR, Barry ST, Robertson JD, Hoff PM, Jürgensmeier JM.

Br J Cancer. 2013 Nov 26;109(11):2765-73. doi: 10.1038/bjc.2013.649. Epub 2013 Oct 22.

16.

Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.

Hansen TF, Carlsen AL, Heegaard NH, Sørensen FB, Jakobsen A.

Br J Cancer. 2015 Feb 17;112(4):624-9. doi: 10.1038/bjc.2014.652. Epub 2015 Jan 13.

17.

Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.

Hansen TF, Nielsen BS, Jakobsen A, Sørensen FB.

Cell Oncol (Dordr). 2013 Jul;36(4):341-50. doi: 10.1007/s13402-013-0139-3. Epub 2013 Jul 10.

PMID:
23838926
18.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
19.

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.

Hansen TF, Christensen Rd, Andersen RF, Garm Spindler KL, Johnsson A, Jakobsen A.

Int J Colorectal Dis. 2012 Jun;27(6):715-20. doi: 10.1007/s00384-011-1382-6. Epub 2011 Dec 6.

PMID:
22139032
20.

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP.

J Clin Oncol. 2012 Oct 10;30(29):3596-603. doi: 10.1200/JCO.2012.42.6031. Epub 2012 Sep 10.

Items per page

Supplemental Content

Write to the Help Desk